PRISM BioLab Co Ltd, a Japanese discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, announced on Monday that it has entered into a drug discovery collaboration with AI drug discovery company Elix Inc, effective 1 April 2025.

This partnership is intended to accelerate PRISM Biolab's research on these challenging molecular targets by combining its proprietary peptide mimetic technology for controlling protein-protein interactions with Elix's AI drug discovery platform, Elix Discovery.

According to PRISM BioLab, the collaboration will expand the AI search range to include previously unconsidered small molecules, enabling efficient identification of promising compounds for traditionally difficult targets and accelerating the creation of breakthrough drug candidates. By leveraging both companies' AI capabilities and medicinal chemistry expertise, the partnership aims to reduce time and costs and improve success rate of drug discovery, ultimately delivering innovative treatments for unmet medical needs.